Predictive value of drug elimination gene polymorphisms on clearance and dose adjustment of sunitinib (Sutent, SU11248) in patients with cancer
Ontology highlight
ABSTRACT: Primary objectives: To observe the correlation between ABCB1 polymorphisms in Exons 13, 22 and 27 and the clearance of sunitinib at steady state.
Primary endpoints: The endpoint of the study is a correlation between sunitinib clearance and toxicityadjusteddose with ABCB1 genotype examining SNPs in exons 13, 22,and 27 as wellas haplotypes of these exons.
DISEASE(S): The Main Group Are Patients With Renal Cell Cancer Currently Being Or About To Be Treated With Sunitinib. Other Diseases With Efficacy Of Sunitinib Are Gastro Intestinal Stromal Cell Tumour (gist).
PROVIDER: 2525144 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA